Ultrasound contrast agent Sonazoid for Injection released for sale

Published: 2012-05-15 06:56:00

Updated: 2012-05-15 06:56:00

GE Healthcare Korea said today that it has rolled out the ultrasound contrast agent Sonazoid for Injection, which has been marketed in Japan since 2007.

Sonazoid for injection was developed jointly by Daiichi Pharmaceutical and GE Healthcare, the healthcare unit of General Electric Company.
...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK